Quadruple Oral Combination Therapy for Type 2 Diabetes Mellitus : glycemic Control by Thiazolidinedione (TZD) or Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitor as an add-on Therapy in Type 2 Diabetes Mellitus After Failure of an Oral Triple Antidiabetic Regimen

In the treatment of type 2 diabetes (T2D), the number of patients requiring combination therapy of oral antidiabetic agents (OADs) is more than 70%. Especially in Korea, the tendency to avoid insulin therapy is relatively higher than other countries, therefore, the need for combination therapy of OADs is quite high. However, according to the current guidelines, clinicians are recommended to prescribe three or fewer OADs as the combination therapy for T2D. Recently, various OADs have been developed, and it is expected that quadruple combination therapy of OADs would be quite effective to lower blood glucose levels. In the present study, the investigators designed the study to compare the efficacy and safety of quadruple combination therapy; thiazolidinedione (TZD) vs. SGLT‐2 inhibitor as an add‐on therapy to triple combination therapy (Metformin, Sulfonylurea, Dipeptidyl peptidase‐4(DPP‐4) inhibitors). Quadruple combination therapy group with the SGLT‐2 inhibitor will be considered as active control group, because it have shown non‐inferior glycemic efficacy to the conventional insulin conversion therapy in a previous clinical study. Patients who could not achieve the target blood glucose level (7%

Epistemonikos ID: 35edab4f23a0831c312f0d93c8851180078cc655
First added on: May 22, 2024